Enliven Therapeutics (ELVN) Insider Trading & Ownership $21.47 -0.91 (-4.07%) (As of 09/17/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)10Amount OfInsider Selling(Last 12 Months)$44.70 M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELVN Insider Buying and Selling by Quarter Ad InvestorPlaceWhy Are Buffett, Bezos, and Musk Fleeing Tech? Here's What To Do Now...The financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumping their tech stocks at a pace we've never seen before. What do they know that's pushing them out? One that Fortune is calling:"The Great Cash Out".Click here to get the details now. Enliven Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/29/2024Joseph P LyssikatosInsiderSell12,000$22.49$269,880.00 8/27/2024Benjamin HohlCFOSell4,250$22.54$95,795.00 8/26/2024Samuel KintzCEOSell12,000$22.89$274,680.00 8/15/2024Richard A HeymanDirectorSell1,270$23.25$29,527.50 7/31/2024Benjamin HohlCFOSell991$27.53$27,282.23 7/31/2024Joseph P LyssikatosInsiderSell3,099$27.56$85,408.44 Big News: How the Upcoming Rate Cut and Elon Musk’s AI Could Transform Your Investments (Ad)The Federal Reserve is almost certainly about to cut interest rates, and history tells us that stocks often rally after such moves. In fact, based on my calculations, in seven out of nine rate-cut cycles since 1981, stocks have surged, delivering an average of 36.3% returns over two years. But that's not all... This time, there's another massive trigger on the horizon – Elon Musk's groundbreaking AI technology.Click here to learn how you can take advantage of these two monumental shifts right now.7/31/2024Richard A HeymanDirectorSell1,702$27.51$46,822.02 7/31/2024Samuel KintzCEOSell2,270$27.56$62,561.20 7/29/2024Benjamin HohlCFOSell5,250$26.68$140,070.00 7/29/2024Joseph P LyssikatosInsiderSell12,000$26.70$320,400.00 7/25/2024Samuel KintzCEOSell12,000$24.92$299,040.00 7/15/2024Anish PatelCOOSell30,978$25.05$775,998.90 7/15/2024Richard A HeymanDirectorSell1,270$24.80$31,496.00 7/12/2024Anish PatelCOOSell17,475$25.07$438,098.25 7/12/2024Benjamin HohlCFOSell3,000$25.07$75,210.00 6/27/2024Benjamin HohlCFOSell4,250$22.57$95,922.50 6/25/2024Samuel KintzCEOSell12,000$21.66$259,920.00 6/6/2024Anish PatelCOOSell1,133$20.06$22,727.98 5/28/2024Benjamin HohlCFOSell4,250$23.18$98,515.00 5/28/2024Samuel KintzCEOSell12,000$23.18$278,160.00 5/16/2024Rishi GuptaDirectorSell1,033,300$22.14$22,877,262.00 5/14/2024Anish PatelCOOSell1,107$25.00$27,675.00 5/9/2024Anish PatelCOOSell260$25.06$6,515.60 5/6/2024Anish PatelCOOSell4,875$22.72$110,760.00 5/3/2024Benjamin HohlCFOSell1,000$22.50$22,500.00 4/29/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 4/29/2024Joseph P. LyssikatosinsiderSell12,000$17.92$215,040.00 4/25/2024Samuel KintzCEOSell12,000$16.89$202,680.00 4/15/2024Richard A HeymanDirectorSell1,270$19.99$25,387.30 4/11/2024Anish PatelCOOSell17,500$25.03$438,025.00 4/11/2024Benjamin HohlCFOSell14,000$24.72$346,080.00 4/11/2024Joseph P. LyssikatosinsiderSell30,000$25.04$751,200.00 4/11/2024Rahul D BallalDirectorSell53,400$23.95$1,278,930.00 4/11/2024Samuel KintzCEOSell47,709$25.04$1,194,633.36 4/8/2024Anish PatelCOOSell4,875$18.60$90,675.00 4/4/2024Rahul D BallalDirectorSell3,485$19.15$66,737.75 4/1/2024Joseph P. LyssikatosinsiderSell12,000$18.60$223,200.00 4/1/2024Rahul D BallalDirectorSell3,237$19.08$61,761.96 3/27/2024Benjamin HohlCFOSell3,250$18.25$59,312.50 3/25/2024Samuel KintzCEOSell12,000$17.56$210,720.00 Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA).3/19/2024Richard A HeymanDirectorSell1,270$14.50$18,415.00 3/6/2024Anish PatelCOOSell4,875$15.64$76,245.00 2/29/2024Joseph P. LyssikatosinsiderSell12,000$16.42$197,040.00 2/27/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 2/15/2024Richard A HeymanDirectorSell1,270$17.42$22,123.40 2/6/2024Anish PatelCOOSell4,875$15.11$73,661.25 1/31/20245Am Partners Vi, LlcMajor ShareholderSell500,000$15.00$7,500,000.00 1/30/2024Richard A HeymanDirectorSell1,270$16.41$20,840.70 1/29/2024Benjamin HohlCFOSell3,250$15.81$51,382.50 1/29/2024Joseph P. LyssikatosinsiderSell12,000$15.85$190,200.00 1/25/2024Samuel KintzCEOSell12,000$15.69$188,280.00 1/22/2024Anish PatelCOOSell4,875$15.13$73,758.75 1/2/2024Anish PatelCOOSell11,000$15.00$165,000.00 1/2/2024Benjamin HohlCFOSell9,383$15.01$140,838.83 12/26/2023Anish PatelCOOSell102$15.01$1,531.02 12/26/2023Benjamin HohlCFOSell100$15.00$1,500.00 12/26/2023Samuel KintzCEOSell12,000$14.64$175,680.00 12/22/2023Anish PatelCOOSell983$15.03$14,774.49 12/22/2023Benjamin HohlCFOSell1,030$15.07$15,522.10 12/22/2023Samuel KintzCEOSell8,175$13.05$106,683.75 12/21/2023Joseph P. LyssikatosinsiderSell20$13.00$260.00 12/21/2023Richard A HeymanDirectorSell7$13.00$91.00 12/20/2023Samuel KintzCEOSell7,779$13.01$101,204.79 12/19/2023Joseph P. LyssikatosinsiderSell200$13.00$2,600.00 12/19/2023Richard A HeymanDirectorSell255$13.00$3,315.00 11/3/2023Joseph P. LyssikatosinsiderSell8,546$13.08$111,781.68 11/3/2023Samuel KintzCEOSell8,026$13.08$104,980.08 9/29/2023Joseph P. LyssikatosinsiderSell12,000$13.62$163,440.00 9/26/20235Am Partners Vi, LlcMajor ShareholderSell197,500$15.00$2,962,500.00 9/25/2023Samuel KintzCEOSell12,000$13.81$165,720.00 (Data available from 1/1/2013 forward) ELVN Insider Trading Activity - Frequently Asked Questions Who is on Enliven Therapeutics's Insider Roster? The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN. What percentage of Enliven Therapeutics stock is owned by insiders? 29.20% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings. Which Enliven Therapeutics insiders have been selling company stock? The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($2,315,446.24), Benjamin Hohl ($1,280,235.66), Joseph P Lyssikatos ($675,688.44), Rahul D Ballal ($1,407,429.71), Richard A Heyman ($198,017.92), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($3,624,943.18). How much insider selling is happening at Enliven Therapeutics? Insiders have sold a total of 2,713,747 Enliven Therapeutics shares in the last 24 months for a total of $51,736,284.83 sold. Enliven Therapeutics Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Compensation: $866.41kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder & Chief Scientific Officer Compensation: $632.67kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Compensation: $686.19kMr. Anish Patel Pharm.D. (Age 43)Co-Founder & COO Mr. Benjamin Hohl (Age 34)CFO & Head of Corporate Development Compensation: $488.5k10 recent tradesDr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development More Insider Trading Tools from MarketBeat Related Companies: Avadel Pharmaceuticals Insider Buying Editas Medicine Insider Buying Delcath Systems Insider Buying Fulcrum Therapeutics Insider Buying Spero Therapeutics Insider Buying bluebird bio Insider Buying Orgenesis Insider Buying Intellia Therapeutics Insider Buying Corcept Therapeutics Insider Buying Perrigo Insider Buying Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Matador Resources Insiders Keep Buying Its Stock, Should You?Top 3 Small-Cap Stocks Insiders Are Buying Right Now3 Small Cap Stocks That Insiders Are BuyingMGM Insiders Bet Big on Its Undervalued Stock3 Small Cap Stocks Insiders Are Actively Buying This page (NASDAQ:ELVN) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredI’m giving you the name of this investment for freeNow that the Federal Reserve lowered interest rates, this investment could easily go up 50%.Porter & Company | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Enliven Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.